← Oncology Approval Tracker

FDA DECISION ·

Yescarta

axicabtagene ciloleucel · Kite Pharma

Accelerated approvalNew or expanded indicationFollicular lymphoma
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Adults with relapsed or refractory follicular lymphoma after at least two lines of systemic therapy.

LAMPGEN ANALYSIS

Why it matters

This accelerated action extended CD19 CAR T therapy to a previously treated indolent lymphoma population.

What research teams should watch

Document histology and prior lines, and plan lead time for referral and cell manufacturing.

PRIMARY RECORDS

Sources